Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST trial of BIIB059 in active cutaneous lupus erythematosus
2020-000727-40Phase 2Active
- Sponsor
- Biogen
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE) comparing BIIB059 with Placebo (2 arms). Primary endpoint: Percentage of participants who achieve a CLA-IGA-R score of 0 or 1. Started Jun 2022; status: active.
02
Drugs
litifilimab
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2020-000727-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000727-40.